Figure 5. Meta-analysis of the use of ACE inhibitors/ARBs on the risk of COVID-19 related severe adverse clinical outcomes defined as admission to the intensive care unit (ICU), the use of assisted ventilation, or death (-26%,pooled OR=0.74, 0.56 to 0.99; p=0.04; I2=78.5%).